U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968845) titled 'A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis' on April 28.
Brief Summary: Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (scarring) of the lungs. As the disease progresses, patients experience loss of lung function and increased breathing problems. LTI-03 is hypothesized to treat IPF by protecting and restoring the function of the oxygen uptake cells and by con...